Prenatal Intravenous Magnesium at 30 to 34 Weeks’ Gestation and Neurodevelopmental Outcomes in Offspring: The MAGENTA Randomized Clinical Trial

Abstract

(JAMA. 2023;330(7):603–614) Preterm infants have a greater risk of cerebral palsy, a common motor disability for which there is no cure. As such, primary prevention is especially important. The use of magnesium sulfate while pregnant has been shown in randomized clinical trials to be helpful for those at risk of early preterm delivery by improving an infant’s chance of survival without cerebral palsy. As a result, magnesium sulfate is recommended for fetal neuroprotection. However, there is a lack of data surrounding the ideal gestational age for using it prenatally.